DE69200757T2 - Pharmazeutische Zusammensetzung zur Inhibierung der Knochenresorption. - Google Patents

Pharmazeutische Zusammensetzung zur Inhibierung der Knochenresorption.

Info

Publication number
DE69200757T2
DE69200757T2 DE69200757T DE69200757T DE69200757T2 DE 69200757 T2 DE69200757 T2 DE 69200757T2 DE 69200757 T DE69200757 T DE 69200757T DE 69200757 T DE69200757 T DE 69200757T DE 69200757 T2 DE69200757 T2 DE 69200757T2
Authority
DE
Germany
Prior art keywords
bone
group
bone resorption
compound
denotes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69200757T
Other languages
German (de)
English (en)
Other versions
DE69200757D1 (de
Inventor
Denis Dr Carniato
Heinrich Dr Englert
Mizuho Inazu
Tsutomu Inoue
Masakazu Katoh
Hiroshi Kitagawa
Hans-Jochen Dr Lang
Ryoichi Satoh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis KK
Original Assignee
Hoechst Japan Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Japan Ltd filed Critical Hoechst Japan Ltd
Publication of DE69200757D1 publication Critical patent/DE69200757D1/de
Application granted granted Critical
Publication of DE69200757T2 publication Critical patent/DE69200757T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69200757T 1991-12-16 1992-12-14 Pharmazeutische Zusammensetzung zur Inhibierung der Knochenresorption. Expired - Fee Related DE69200757T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP33176791 1991-12-16
JP23914492A JP3502403B2 (ja) 1991-12-16 1992-09-08 骨吸収抑制剤

Publications (2)

Publication Number Publication Date
DE69200757D1 DE69200757D1 (de) 1995-01-12
DE69200757T2 true DE69200757T2 (de) 1995-05-11

Family

ID=26534099

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69200757T Expired - Fee Related DE69200757T2 (de) 1991-12-16 1992-12-14 Pharmazeutische Zusammensetzung zur Inhibierung der Knochenresorption.

Country Status (10)

Country Link
US (1) US5317029A (enExample)
EP (1) EP0547545B1 (enExample)
JP (1) JP3502403B2 (enExample)
KR (1) KR100257496B1 (enExample)
AT (1) ATE114465T1 (enExample)
CA (1) CA2085421A1 (enExample)
DE (1) DE69200757T2 (enExample)
DK (1) DK0547545T3 (enExample)
ES (1) ES2066546T3 (enExample)
TW (1) TW223016B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5280040A (en) * 1993-03-11 1994-01-18 Zymogenetics, Inc. Methods for reducing bone loss using centchroman derivatives
US5837702A (en) * 1993-10-07 1998-11-17 Bristol-Myers Squibb Co. 4-arylamino-benzopyran and related compounds
US5389646A (en) * 1993-12-30 1995-02-14 Zymogenetics, Inc. Methods for treatment and prevention of bone loss using 2,3-benzopyrans
GB9408577D0 (en) * 1994-04-29 1994-06-22 Fujisawa Pharmaceutical Co New compound
US5629429A (en) * 1995-06-07 1997-05-13 Bristol-Myers Squibb Company Process for preparing 4-arylamino-benzopyran and related compounds
US5612370A (en) * 1995-06-07 1997-03-18 Bristol-Myers Squibb Company Phenylglycine and phenylalaninen amido benzopyran derivatives
US5869478A (en) * 1995-06-07 1999-02-09 Bristol-Myers Squibb Company Sulfonamido substituted benzopyran derivatives
US5612323A (en) * 1995-06-07 1997-03-18 Bristol-Myers Squibb Company Phosphinic ester substituted benzopyran derivatives
EP0783888A1 (en) * 1995-12-26 1997-07-16 Sankyo Company Limited Use of troglitazone and related thiazolidinediones in the manufacture of a medicament for the treatment and prophylaxis of osteoporosis
WO2004028444A2 (en) * 1999-06-02 2004-04-08 Scantibodies Laboratory, Inc. Parathyroid hormone antagonists and uses thereof
US20080108086A1 (en) * 1999-06-02 2008-05-08 Cantor Thomas L Parathyroid hormone antagonists and uses thereof
KR100389127B1 (ko) * 2000-10-09 2003-06-25 동부한농화학 주식회사 벤조피라닐 헤테로고리 유도체, 그의 제조방법 및 그를포함하는 약학적 조성물
TWI396543B (zh) * 2005-05-12 2013-05-21 Sankyo Co 取代丙烯醯胺衍生物及含有它之醫藥組成物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZM7682A1 (en) * 1981-09-25 1983-05-23 Beecham Group Plc Active compounds
EP0091748B1 (en) * 1982-04-08 1986-06-18 Beecham Group Plc Antihypertensive benzopyranols
JPS58219183A (ja) * 1982-04-28 1983-12-20 ビ−チヤム・グル−プ・ピ−エルシ− 新規なクロマノ−ル，その製法及びそれらを含む製薬組成物
EP0093535B1 (en) * 1982-04-28 1986-12-30 Beecham Group Plc Novel chromenes and chromans
GB8513369D0 (en) * 1985-05-28 1985-07-03 Beecham Group Plc Treatment
DE3703227A1 (de) * 1987-02-04 1988-08-18 Hoechst Ag Substituierte 3,4-dihydro-2h-benzopyrane, verfahren zu ihrer herstellung, ihre verwendung sowie pharmazeutische praeparate auf basis dieser verbindungen
DE3823533A1 (de) * 1988-07-12 1990-02-08 Beiersdorf Ag Substituierte 4-heterocyclyl-2h-benzo(b)pyrane, verfahren und 4-hydroxy-3-brom-, 3,4-oxiranyl-3,4-dehydro-2h-benzo(b)pyrane als zwischenprodukte zu ihrer herstellung, sowie sie enthaltende pharmazeutsche praeparate

Also Published As

Publication number Publication date
EP0547545A1 (en) 1993-06-23
CA2085421A1 (en) 1993-06-17
JPH05221860A (ja) 1993-08-31
KR100257496B1 (ko) 2000-08-01
TW223016B (enExample) 1994-05-01
US5317029A (en) 1994-05-31
EP0547545B1 (en) 1994-11-30
DE69200757D1 (de) 1995-01-12
ATE114465T1 (de) 1994-12-15
DK0547545T3 (da) 1995-05-15
KR930012036A (ko) 1993-07-20
JP3502403B2 (ja) 2004-03-02
ES2066546T3 (es) 1995-03-01

Similar Documents

Publication Publication Date Title
DE3875285T2 (de) Verwendung von salzen der n-acetylneuraminsaeure zur herstellung eines arzneimittels zum abschwellen der nasenschleimhaut.
DE68914292T2 (de) Zusammensetzung zur Behandlung von ischämischen Störungen in Organen.
DE69200757T2 (de) Pharmazeutische Zusammensetzung zur Inhibierung der Knochenresorption.
DE60004348T2 (de) Kombinierte vorbereitungen, die morpholin anthracyclin und platin derivate
DE3486150T2 (de) Zusammensetzungen zur propylaktischen behandlung von osteitis und osteomyelitis.
DE4212640A1 (de) Betablocker enthaltende, stabile arzneimittelzusammensetzungen mit regulierter wirkstoffabgabe fuer orale verabreichung und verfahren zu ihrer herstellung
EP0185210B1 (de) Verwendung von Dipeptidderivaten für die Herstellung von Arzneimitteln zur Behandlung von an amyotropher Lateralsklerose Erkrankten
DE3201865C2 (de) Verwendung von 6-Amino-1-hydroxyhexan-1,1- diphosphonsäure und Derivaten davon zur Behandlung der Osteopathie
DE69612510T2 (de) Verwendung von 1-(2-naphtylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridin zur herstellung eines medikaments zur behandlung der amyotrophen lateralsklerode
DE69511448T2 (de) Verwendung von Phosphorsäurediester-Verbindungen zur Unterdrückung von Krebsmetastasen in der Leber
DE3033545A1 (de) Verwendung bekannter antiallergener mittel bei der bekaempfung von pathologischen mineralresorptionszustaenden
DE69023939T2 (de) Förderung der Osteogenese durch Verwendung von Vitamin D-Derivaten.
WO2004012744A1 (de) Anwendung von alkylphosphocholinen in kombination mit antitumormedikamenten
EP1001756B1 (de) Synergistisch wirkende zusammensetzungen zur selektiven bekämpfung von tumorgewebe
DE69534923T2 (de) Anabolische zubereitung für knochenmasse enthaltend olpadronat
DE69125204T2 (de) Therapeutische Anwendung von Histamin-H3-Agonisten, neue Wirkstoffe und Verwendung zur Herstellung von Arzneimitteln
DE3619426A1 (de) Mittel zur erhoehung der widerstandskraft gegen erkaeltungskrankheiten bei patienten mit eingeschraenkter lungenfunktion
DE68905424T2 (de) Alpha-glucosidaseinhibitor zur foerderung der calciumabsorption.
DE2451933C2 (enExample)
WO2000001392B1 (de) 1-octadecyl-2-methyl-sn-glycero-3-phosphocholin (et180ch3) zur behandlung von humanen mammakarzinomen
DE3011274A1 (de) Synergistische strahlenschuetzende pharmazeutische praeparate sowie deren herstellung
DE69600714T2 (de) Antiallergische Zusammensetzung enthaltend eine Phosphorsäurediester-Verbindung
DE3141970A1 (de) Arzneimittel zur behandlung der durch den virus der herpes-gruppe erzeugten erkrankungen
EP0291751B1 (de) Pharmazeutisches Kombinationspräparat
DE3518559A1 (de) Neue verwendung von dihydroergotamin

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee